Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 45Breast Neoplasms 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Non-Hodgkin 39Multiple Myeloma 35Leukemia 34Melanoma 32Leukemia, Lymphocytic, Chronic, B-Cell 32Recurrence 31Leukemia, Myeloid, Acute 28Lymphoma, Follicular 27Lymphoma, B-Cell 25Ovarian Neoplasms 24Lymphoma, Mantle-Cell 23Neoplasm Metastasis 22Hematologic Neoplasms 19Pancreatic Neoplasms 18Myelodysplastic Syndromes 18Hodgkin Disease 18Burkitt Lymphoma 16Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Colorectal Neoplasms 12Stomach Neoplasms 11Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Carcinoma, Hepatocellular 9

Interventions

ixazomib 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Alzheimer Disease × Cyclophosphamide × Clear all
NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡